INCB7839 has also been tested in clinical trials, with promising results in phase I/II trials of Trastuzumab-based HER2+ breast cancer therapy by inhibiting HER2 shedding (NCT01254136), and evaluated in phase I trials for recurrent or progressive high-grade gliomas (NCT04295759). This evidence concerns the gene ERBB2 and breast carcinoma.